In Conversation

Singapore Pharma Report 2021
Latest Reports
Singapore Pharma Report 2021
- 2021
With outstanding fundamentals, including top-class universities and hospitals, a government cognizant of the benefits that a robust research-based biopharma industry brings, and straightforward business processes, Singapore has long been a hub for life science companies looking to penetrate the vast Asia-Pacific region. This exclusive new report deep dives into Singapore’s key attractions for international investors, from how its excellence in regulatory science has created a testbed for next-generation therapies and products, to the nation’s status as an advanced biomanufacturing hub for the region, to its increasing focus on translational research, building up an enabling ecosystem for biotechs seeking to…
Switzerland Pharma Report June 2021
Latest Reports
Switzerland Pharma Report June 2021
- 2021
Switzerland continues to hold its own as a focal point for innovation and discovery in global medical science and ranks very highly on the radar of both Big Pharma and the international biotech community alike. As well as Switzerland’s continuing relevance to the European and global pharma industry, pharma is truly at the core of the Swiss economy, generating a full 5.4 percent of the country’s GDP, a number which rises to 9.2 percent when indirect effects are factored in. Moreover, the industry now accounts for a massive 45 percent of Switzerland’s total exports. This exclusive and wide-ranging new…
Switzerland Pharma Report February 2021
Latest Reports
Switzerland Pharma Report February 2021
- 2021
Switzerland, long held up as an innovation powerhouse able to hold its own against the considerably larger neighbouring life science markets of France and Germany, has, in some respects, found the going tougher of late. The country’s domestic drug market has been enduring a sticky patch and could only muster a modest growth rate of 2.8 percent in 2020 as policymakers grappled with issues more familiar to the rest of the continent such as cost-containment. Nonetheless, the country’s life science companies continue to achieve global acclaim and attract the attention of investors the world over.   As one of…
Norway Pharma Report 2021
Latest Reports
Norway Pharma Report 2021
- 2021
A bastion of equality with high levels of healthcare spending, excellent research and universities, a global commitment to improving health outcomes, and a deeply entrenched digital footprint, Norway is full of potential as a life sciences investment destination. This potential, however, has largely remained untapped until now, as the country has focused on its more established oil & gas and fishing industries. Without true governmental support, the Norwegian life sciences industry has been somewhat neglected, with clinical trials numbers declining in recent years and multinational companies feeling hesitant about the market access situation for their most innovative treatments. Nevertheless,…
USA Pharma Report 2020
Latest Reports
USA Pharma Report 2020
- 2020
The inaugural edition of the US Healthcare and Life Sciences Review has collated comments and insights from stakeholders across regulators, health insurers, pharma and biotech companies, as well as patient and industry associations, to provide an incisive snapshot of the US healthcare industry during one of its most defining periods, look at how far the sector has come and ultimately, how much further still it has to go, in order to achieve its fundamental mission: delivering innovative, quality and life-changing therapies in an accessible and sustainable manner. This exclusive new report is an extensive compilation of insights into the…
USA Pharma Data Report October 2020
Latest Reports
USA Pharma Data Report October 2020
- 2020
HCLS Review USA Data is an extensive compilation of data and infographics from the world’s largest and most important pharmaceutical market. US sales of drugs accounted for 48 percent of the global market for pharmaceuticals in 2019 and pharma market spending is on the rise, with Americans projected to be spending between USD 635 and 655 billion on medicine by 2023. Moreover, the USA is the world’s largest research and development engine, with an estimated USD 60 billion spent every year for this purpose, helping create the innovative treatments of tomorrow. This exclusive new 19-page report contains up-to-date information…
Middle East & North Africa Pharma Data By Country Report 2020
Latest Reports
Middle East & North Africa Pharma Data By Country Report 2020
- 2020
HCLS Review Middle East & North Africa Data by Country is an extensive compilation of the latest country-specific data on economies, healthcare, pharmaceutical industries, and R&D in some of the region’s most dynamic markets. This new 51-page report contains data from Algeria, Egypt, Iran, Morocco, Saudi Arabia, Turkey, and the United Arab Emirates and is an invaluable resource for anyone looking for up-to-date statistics and trends on these key geographies.   The MENA region is rapidly developing and extremely diverse, spanning both countries at the cutting-edge of innovation and technology as well as emerging economies. According to TradeArabia, the…
Asia-Pacific Pharma Data by Country Report 2020
Latest Reports
Asia-Pacific Pharma Data by Country Report 2020
- 2020
HCLS Review Asia-Pacific Data by Country is an extensive compilation of the latest country-specific data on economies, healthcare, pharmaceutical industries, and R&D in some of the region’s most dynamic markets. This new 38-page report contains data from Australia, Hong Kong SAR, Japan, PR China, South Korea, and Taiwan and is an invaluable resource for anyone looking for up-to-date statistics and trends on these key geographies.   Asia-Pacific is rapidly developing and extremely diverse, spanning both countries at the cutting-edge of innovation and technology as well as emerging economies. According to the Business Research Company, the territory's pharmaceutical market stands…
Belgium Pharma Report 2020
Latest Reports
Belgium Pharma Report 2020
- 2020
This exclusive new report examines how Belgium has been able to establish itself as the ‘Pharma Valley of Europe’, famed for the quality and breadth of its medical research, the scale and complexity of its manufacturing infrastructure, and its multilingual, highly skilled, and industry savvy talent pool. It also looks at the wide variety of pharma multinationals who have chosen to situate regional headquarters, strategic hubs, as well as R&D and manufacturing sites in the country. Other topics covered include how the country’s domestic market has evolved since the 2015 ‘Pact for the Future’ between industry and government, the…
Europe Pharma Data by Country Report 2020
Latest Reports
Europe Pharma Data by Country Report 2020
- 2020
HCLS Review Europe Data by Country is an extensive compilation of the latest country-specific data on economies, healthcare, pharma markets, and R&D across Europe. This new 95-page report contains data from 17 different countries and is an invaluable resource for anyone looking for up-to-date statistics and trends in Europe’s most important markets. The countries included in this report are Belgium, Cyprus, the Czech Republic, France, Germany, Greece, Hungary, Ireland, Italy, Malta, Poland, Portugal, Romania, Serbia, Spain, Sweden, and the UK.
We use cookies to ensure that we give you the best experience on our site. For more info click here